Mylan CEO on FDA-approved biosimilar, Trump's drug price plan
Nearly two years after taking tremendous heat for the rising cost of EpiPens, pharmaceutical giant Mylan is making strides in the fast-growing biosimilar market. Biosimilars are drugs and devices made to be similar to already-approved products, potentially lowering the cost of treatment. Mylan won FDA approval last week for a biosimilar drug designed to help some cancer patients reduce infection risk during chemotherapy. Mylan CEO Heather Bresch joins "CBS This Morning" to explain how biosimilars could translate to patient savings, what the company learned from the EpiPen debacle, and why she applauds President Trump's plan to reduce drug costs.